Trending...
- Governor Newsom honors fallen California Highway Patrol Officer Miguel Cano - 104
- Governor Newsom marks historic expansion of California's Film and Television Tax Credit Program, announces 16 new projects to film in the Golden State
- California: Governor Newsom announces appointments 7.2.25
VANCOUVER, British Columbia - Californer -- Investors are excited about biotechnology stocks in the time of the novel coronavirus. The Wall Street Journal reports that small and medium biotech stocks are near record highs, with a 60% resurgence in value since March.
Indeed, the time is ripe for biotech companies to cash in on COVID-19 via pursuit of novel drug therapies and vaccines for the condition, which currently has no cure. But risky biotech companies are taking advantage of the COVID-19 market in an effort to gain more investors for pharma products which may ultimately fail.
Sources of Risk in Biotech and Pharma
The biotech industry is notorious for its high risk, so in a COVID-19 world, more than ever, investors need to look for long-term value from prospective biotech investments. Sources of risk in the biotechnology and pharma industry – even before the current environment – include:
A key aspect of investing in biotech has always been to minimize the inherent risk as much as possible. This means looking at the company's foundation and whether they are an established leader in the field. Instead of examining how companies are faring in the COVID-19 world, consider tried-and-true leaders in pharma and biotech, which are likely to play a major effort in COVID-19 due to their leadership in the space.
Opting for low-risk stocks which performed well before the economic downturn associated with the ongoing pandemic can help improve the success of your portfolio in the long term. These companies include:
The Bottom Line
Biotech investors should focus on long-term investing strategies with proven, big pharma companies. They should avoid small, undercapitalized biotech companies that are simply chasing trends.
Indeed, the time is ripe for biotech companies to cash in on COVID-19 via pursuit of novel drug therapies and vaccines for the condition, which currently has no cure. But risky biotech companies are taking advantage of the COVID-19 market in an effort to gain more investors for pharma products which may ultimately fail.
Sources of Risk in Biotech and Pharma
The biotech industry is notorious for its high risk, so in a COVID-19 world, more than ever, investors need to look for long-term value from prospective biotech investments. Sources of risk in the biotechnology and pharma industry – even before the current environment – include:
- Companies' acquisition by other companies
Biotech is a fast-paced and dynamic world, and companies may join forces to work on a shared goal. GlaxoSmithKline has acquired 21 companies over the past decade alone, according to Crunchbase. In an alternative scenario, two companies may race towards a cure, with one company inevitably losing out. - Drugs failing in clinical trials after seeming promising in the preclinical world
While it may take ten years just for a drug to enter the clinical trials process from the laboratory, this protracted timeframe may not spell success. In 2019, Merck's cancer immunotherapy Keytruda, one of the company's strongest drugs, failed in Phase 3 clinical trials for treatment of a specific type of liver cancer. Also in 2019, Bristol Myers Squibb's Obdivo failed in a Phase 3 brain cancer trial.
More on The Californer- Heritage at South Brunswick Offers Immediate Townhome Appointments and Special Mortgage Incentive Fast-Moving Sales
- Sam Sammane wins Literary Titan Award for Republic of Mars, a haunting sci-fi debut on memory
- Fair Trade LA, The Tote Project, and Fair Trade USA™ Distribute 100 "Fair Care Packages" to Families Affected by Los Angeles Fires
- For Third Consecutive Year, ELEVATE Recognized as Star Performer & Major Contender by Everest Group
- NASA Collaborative Agreement for Supply of Thin-Film Solar Tech for Orbital Application to Advance Development of Thin-Film PV Power Beaming: $ASTI
- Adverse effects which cause drugs to promptly be pulled off the market
In 2004, Merck recalled another blockbuster drug, the painkiller Vioxx, after patients began suffering heart attacks and strokes.
A key aspect of investing in biotech has always been to minimize the inherent risk as much as possible. This means looking at the company's foundation and whether they are an established leader in the field. Instead of examining how companies are faring in the COVID-19 world, consider tried-and-true leaders in pharma and biotech, which are likely to play a major effort in COVID-19 due to their leadership in the space.
Opting for low-risk stocks which performed well before the economic downturn associated with the ongoing pandemic can help improve the success of your portfolio in the long term. These companies include:
- Johnson and Johnson (JNJ), a company with $82.8 billion in sales, which recently announced work on a COVID-19 vaccine and is listed at #34 in Forbes Global 2000 2020.
- Abbott Labs (ABT), which recently unveiled 5-minute point-of-care testing for the novel coronavirus which can be used at pharmacies and doctor's offices. Upon this news, the stock price rose nearly 50% from its low price of approximately $69 during the lowest point of the economic downturn to about $90 per share.
More on The Californer- Shoot 'Em Up Classic Undeadline Coming to America & Europe for the First Time in New Collector's Set
- Exciting New Era of Sports, Entertainment & Gaming Innovation Spotlighted by Rebrand of Expanding AI Driven, Online Fan Engagement Company: SEGG Media
- FANATICS AND COMPLEX PRESENT <BLACKPINK IN YOUR AREA> LEAGUE COLLECTION TO CELEBRATE THEIR COMEBACK
- Service Ninjas Debuts First-of-Its-Kind "Membership" Platform for Home Service Pros
- Project Management Institute San Francisco and TalentCheetah Inc. Announce New Strategic Partnership
- Gilead Sciences (GLD), a company listed at #186 in the Forbes Global 2000 2020, which recently experienced new popularity as its antiviral treatment, Remdesivir, obtained fast-track FDA approval as a treatment for COVID-19.
- Pharma giant AstraZeneca (AZN) recently announced a landmark agreement with Oxford University towards making a COVID-19 vaccine a reality for millions around the world.
The Bottom Line
Biotech investors should focus on long-term investing strategies with proven, big pharma companies. They should avoid small, undercapitalized biotech companies that are simply chasing trends.
Source: Braeden Lichti
Filed Under: Science
0 Comments
Latest on The Californer
- Jason Koch: Pioneering the Future of Real Estate Development in New Jersey
- Amid Trump's assault on public lands, California conserves over one million acres of land and coastal waters in just one year
- California: Governor Newsom announces appointments 7.7.25
- City of Long Beach to Upgrade Its Internet Infrastructure to Enhance City Network Reliability and Performance
- Groflex Named One of the Top 100 Manufacturing Startups in San Francisco by F6S
- BofA Directs Additional $1 Million to Los Angeles Nonprofits for Evolving Fire Recovery Needs
- Introducing LK Blue: The Cool-Girl Denim Brand That's Redefining LA Style Launches E-Commerce
- THINKWARE Announces Prime Day Deals on Best-Selling Dash Cams
- Zeta Sky Strengthens Cybersecurity Support for Ontario Businesses Facing Rising Identity & Complian
- Bach and Beyond: Cellists Return to the Beach for 2nd Annual Bethany Beach Cellofest
- Boleros de Noche presents "Marisoul y Los Hermanos Carlos" & "Bolero Soul" at The Ford
- Krispy Kreme, Inc. (DNUT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- The 17th Annual Hola Mexico Film Festival presented by Toyota, September 12-20, during Hispanic Heritage Month, Official Poster Reveal
- NR7 Miner launches zero-cost USDT cloud mining service: daily stable income + referral rewards for double profit
- "The Grateful Dead — 60 Years in San Francisco" - Pantheon Media Launches New Podcast Series and Interactive "Hit Replay" App
- Deaths Spur Closures, but Troubled Teen Camps Must Be Banned, CCHR Warns
- Kiavi Expands Leadership Team to Further Bolster Construction Lending Growth
- Palmer Lake Wine Festival To Build Bridges in Small Mountain Community, Highlight Local Businesses
- Swim Up Hill Appoints Ambassador Lawson, Rep. Towns, and Banker Henderson to Board of Directors
- Paralympic Medalist Jamal Hill Launches Official Road to LA28 Campaign and $3M Corporate Fundraising Initiative